Clinical trial
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation…
NCT00393380 · The Emmes Company, LLC, Industry · Terminated
Key facts
| NCT number | NCT00393380 |
|---|---|
| Title | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor |
| Official title | A Phase II Study of Parathyroid Hormone Following Myeloablative Sequential Unrelated Cord Blood Transplantation |
| Lead sponsor | The Emmes Company, LLC, Industry |
| Collaborators | National Heart, Lung, and Blood Institute (NHLBI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia, Myeloid, Chronic, Anemia, Aplastic, Myelofibrosis, Lymphoma, Hodgkin Disease, Lymphocytic, Myelocytic and 1 more |
| Intervention type | Drug |
| Interventions | Parathyroid Hormone (teriparatide) |
| Enrollment | 13 |
| Start date | Sep 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Mar 1, 2012 |
| First posted | Oct 27, 2006 |
| Last update posted | Apr 29, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: